We are live on ! Find out more
AEON icon

AEON Biopharma
AEON

85 hedge funds and large institutions have $248M invested in AEON Biopharma in 2022 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 13 increasing their positions, 16 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

63% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 8

12% more capital invested

Capital invested by funds: $222M → $248M (+$26.3M)

5% more funds holding

Funds holding: 81 → 85 (+4)

0.07% more ownership

Funds ownership: 1.17% → 1.24% (+0.07%)

19% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 16

Holders
85
Holders Change
+4
Holders Change %
+4.94%
% of All Funds
1.37%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
13
Increased
13
Reduced
16
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CIM
Cowen Investment Management
New York
+$5.72M
2
WCMNY
Westchester Capital Management (New York)
New York
+$5.5M
3
MC
Meteora Capital
Florida
+$5.26M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$3.87M
5
DFCM
Dark Forest Capital Management
Puerto Rico
+$3.01M

Top Sellers

Rank Fund Capital Flow
1
UOC
UBS O'Connor
Illinois
-$4.68M
2
Citadel Advisors
Citadel Advisors
Florida
-$4.12M
3
Parallax Volatility Advisers
Parallax Volatility Advisers
California
-$3.87M
4
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
-$3.43M
5
Calamos Advisors
Calamos Advisors
Illinois
-$2.46M
Name Holding Trade Value Shares
Change 		Change in
Stake
RL
51
RPO LLC
Connecticut
$861K +$176K +246 +26%
CC
52
Centiva Capital
New York
$839K – – –
Ohio Public Employees Retirement System (OPERS)
53
Ohio Public Employees Retirement System (OPERS)
Ohio
$756K – – –
PCM
54
Prelude Capital Management
New York
$652K +$646K +901 New
ASM
55
ATW SPAC Management
New York
$633K – – –
Susquehanna International Group
56
Susquehanna International Group
Pennsylvania
$621K +$107K +150 +21%
EC
57
Elequin Capital
New York
$585K +$572K +798 +7,980%
COPPSERS
58
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
$503K – – –
SCM
59
Segantii Capital Management
Hong Kong
$503K – – –
HF
60
HRT Financial
New York
$502K -$13.6K -19 -3%
CCM
61
Context Capital Management
California
$498K – – –
AR
62
Advisory Research
Illinois
$479K – – –
SSA
63
Schonfeld Strategic Advisors
New York
$452K -$204K -285 -31%
Blackstone Inc
64
Blackstone Inc
New York
$403K – – –
NAM
65
Nexpoint Asset Management
Texas
$400K – – –
LA
66
Linden Advisors
New York
$375K – – –
ACA
67
Arena Capital Advisors
California
$308K – – –
WAM
68
Wolverine Asset Management
Illinois
$278K -$294K -410 -52%
E
69
Ergoteles
New York
$262K +$260K +363 New
CCM
70
Cinctive Capital Management
New York
$251K – – –
AGC
71
Angelo Gordon & Co
New York
$251K – – –
GCWM
72
Graham Capital Wealth Management
District of Columbia
$251K +$249K +347 New
TI
73
Tidal Investments
Wisconsin
$248K – – –
RCM
74
Robinson Capital Management
Michigan
$248K – – –
KKRC
75
Kohlberg Kravis Roberts & Co
New York
$223K – – –
1 2
3
4

AEON Hedge Fund Activity: Q4 2022 in Review

85 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma (AEON) for Q4 2022, worth a combined $248M — up 12% from $222M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new AEON positions and 8 closed out — a net gain of 5 holders — while 13 added to existing stakes and 16 trimmed.

The largest buyer was Cowen Investment Management, opening a new position worth an estimated $5.72M. The largest seller was UBS O'Connor, exiting entirely with an estimated $4.68M sold.

  • 85 institutional investors held AEON Biopharma (AEON) as of Q4 2022, up from 81 in Q3 2022.
  • Funds reported $248M of AEON Biopharma stock for Q4 2022, up 12% quarter-over-quarter.
  • 13 funds opened new AEON Biopharma positions in Q4 2022 and 8 closed out, a net change of +5 holders.
  • The largest AEON Biopharma buyer in Q4 2022 was Cowen Investment Management, an estimated $5.72M added.
  • The largest AEON Biopharma seller in Q4 2022 was UBS O'Connor, an estimated $4.68M sold.

Based on aggregated 13F filings for Q4 2022.